Literature DB >> 8009838

Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors.

N L Riggs1, S J Little, D D Richman, J C Guatelli.   

Abstract

The replication of HIV-1 mutants containing altered splice acceptor sequences was studied. The splice acceptor sites 5' of the essential tat and rev AUG codons were altered to eliminate specifically spliced species from the viral repertoire of mRNAs. All splice site mutants were attenuated or fully defective. Mutation of the tat splice acceptor (exon 4) caused loss of the mRNA species containing exon 4 and resulted in an attenuated but replication-competent phenotype. Mutation of the rev splice acceptor sites resulted in viral genomes that failed to propagate in vitro. Mutation of the more 5' of the two major rev acceptors (exon 4A) caused loss of the mRNA species containing exon 4A together with a compensatory increase in use of the more 3' of the rev acceptors (exon 4B). Mutation of the splice acceptor for exon 4B caused the unexpected loss of both exon 4A- and 4B-containing mRNAs. In addition to these effects on the rev splice acceptors, mutations at the 4A and 4B sites also resulted in decreased use of the tat splice site (exon 4) located 175 nucleotides upstream. These effects on utilization of the tat splice acceptor site may explain the requirement for tat to efficiently complement these mutants. The 4A mutant was complemented by tat but not by rev. The 4B mutant was complemented by rev but required both tat and rev for maximum complementation. These data suggested a cooperativity among these splice sites necessary for efficient viral replication. They also indicated that while viral replication persisted at low levels in the absence of splicing to the known site 5' of the tat AUG, failure to splice to at least one of the two major sites 5' of the rev AUG resulted in insufficient rev activity for replication competence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8009838     DOI: 10.1006/viro.1994.1342

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains.

Authors:  P S Bilodeau; J K Domsic; C M Stoltzfus
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs.

Authors:  Jenny L Anderson; Adam T Johnson; Jane L Howard; Damian F J Purcell
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.

Authors:  Reem Berro; Kylene Kehn; Cynthia de la Fuente; Anne Pumfery; Richard Adair; John Wade; Anamaris M Colberg-Poley; John Hiscott; Fatah Kashanchi
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing.

Authors:  Reem Berro; Caitlin Pedati; Kylene Kehn-Hall; Weilin Wu; Zachary Klase; Yasmine Even; Anne-Marie Genevière; Tatiana Ammosova; Sergei Nekhai; Fatah Kashanchi
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

5.  Tat-independent replication of human immunodeficiency viruses.

Authors:  L Luznik; G Kraus; J Guatelli; D Richman; F Wong-Staal
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

6.  Sequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes.

Authors:  Yolanda Vega; Elena Delgado; Jorge de la Barrera; Cristina Carrera; Ángel Zaballos; Isabel Cuesta; Ana Mariño; Antonio Ocampo; Celia Miralles; Sonia Pérez-Castro; Hortensia Álvarez; Isabel López-Miragaya; Elena García-Bodas; Francisco Díez-Fuertes; Michael M Thomson
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.